Patient immunogenetics, cytogenetics, and mutational data
| Case . | Progressive disease . | Diagnosis at progression . | Time to progression, mo . | Overall survival, mo . | Presentation paraprotein, g/L . | IGHV gene usage . | % IGVH identity . | Key cytogenetics abnormalities . | Candidate gene mutations . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Yes | SLLU | 147 | 177.48 | No | V5-51 | 89.7 | del(3q) | None |
| 2 | Yes | SMZL | 65 | 89.49 | No | V3-64*01/*02 | 92.36 | *CK inc i(17)(q10) | TP53 |
| 3 | Yes | SMZL H | 66 | 134 | Mk | V3-30*03/*18/V3-30-5*01 | 95.49 | None | MYD88 |
| 4 | Yes | SMZL | 119 | 164.44 | No | V4-34*01/*02/*07 | 96.41 | del(14q) | None |
| 5 | Yes | SMZL | 47 | 51.09 | No | V1-2*04 | 98.13 | del(14q) | KLF2, N0TCH2 |
| 6 | Yes | MZL H | 69 | 118.51 | No | V4-34*01/*02 | 94.14 | CK | TNFAIP3 |
| 7 | Yes | SMZL H | 57 | 45.9 | No | V5-51*01 | 96.63 | dup(3q) | None |
| 8 | Yes | LPL H | 150 | 35.94 | GK 1.0 | V4-34*01/*02 | 93.47 | CK | MYD88 |
| 9 | Yes | SLLU | 175 | 269 | ML 1.7 | V3-73*02 | 96.6 | t(2;7) | MYD88 |
| 10 | No | na | na | 171.86 | No | V3-66*01/*04 | 87.37 | None | None |
| 11 | No | na | na | 95.57 | No | V6-1*01 | 96.63 | +12 | None |
| 12 | No | na | na | 115.68 | No | V4-34*01/*02/*12 | 89.8 | +12 | None |
| 13 | No | na | na | 136.51 | No | V4-4*02 | 96.37 | None | CCND3 |
| 14 | No | na | na | 29.73 | GK 9.8 | V3-23*01/V3-23D*01 | 93.4 | +12 | MYD88 |
| 15 | No | na | na | 39.39 | No | V4-59*01 | 95.51 | i(17)(q10) | TP53, CCND3 |
| 16 | No | na | na | 53.85 | No | V3-66*02 | 100 | None | None |
| 17 | No | na | na | 126.78 | No | V4-59*01 | 97.54 | None | None |
| 18 | No | na | na | 39.66 | No | V3-7*02 | 96.88 | del(7q), +12 | TP53, CCND3 |
| 19 | No | na | na | 107.89 | GK 5.2 | V3-7*01 | 95.49 | None | MYD88 |
| 20 | No | na | na | 19.88 | MK 0.5 | V1-2*04 | 100 | None | None |
| 21 | No | na | na | 105 | No | V4-38-2*01 | 92.74 | None | None |
| 22 | No | na | na | 96.16 | No | V6-1*01(9 bp ins), V4-59*01 | 98.32, 91.93 | +3,+12, i(17)(q10) | None |
| 23 | No | na | na | 90.94 | No | V4-34*01/*02 | 95.92 | None | None |
| 24 | No | na | na | 88.41 | No | V4-34*01/*02 | 92.65 | None | None |
| 25 | No | na | na | 40.77 | No | V1-69*01/*11/*12/V1-69D*01 | 89.51 | None | None |
| 26 | No | na | na | 82 | ML trace | V4-34*01 | 100 | del(7q) | None |
| 27 | No | na | na | 149.13 | No | V4-30-2*01 | 91.7 | del(14q) | None |
| 28 | No | na | na | 75.43 | No | V3-9*01 | 93.06 | None | MAP2K1 |
| 29 | No | na | na | 160.72 | GK trace | V3-21*01/*02 | 94.76 | del(7q) | None |
| 30 | No | na | na | 68.34 | No | V1-3*01 | 93.85 | i(17)(q10) | None |
| 31 | No | na | na | 105.13 | No | V4-39*01 | 96.41 | None | None |
| 32 | No | na | na | 133.55 | No | V4-34*01 | 100 | del(7q) | None |
| 33 | No | na | na | 126.32 | MK trace | . | . | i(17)(q10) | None |
| 34 | No | na | na | 146.92 | No | V4-39*01 | 94.07 | +12 | None |
| 35 | No | na | na | 130.83 | No | V5-51*01 | 97.98 | None | None |
| 36 | No | na | na | 5192 | No | V3-23*01/V3-23D*01 | 96.18 | i(17)(q10) | None |
| 37 | No | na | na | 153.53 | GL trace | V1-69-2*01 | 96.63 | None | None |
| Case . | Progressive disease . | Diagnosis at progression . | Time to progression, mo . | Overall survival, mo . | Presentation paraprotein, g/L . | IGHV gene usage . | % IGVH identity . | Key cytogenetics abnormalities . | Candidate gene mutations . |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Yes | SLLU | 147 | 177.48 | No | V5-51 | 89.7 | del(3q) | None |
| 2 | Yes | SMZL | 65 | 89.49 | No | V3-64*01/*02 | 92.36 | *CK inc i(17)(q10) | TP53 |
| 3 | Yes | SMZL H | 66 | 134 | Mk | V3-30*03/*18/V3-30-5*01 | 95.49 | None | MYD88 |
| 4 | Yes | SMZL | 119 | 164.44 | No | V4-34*01/*02/*07 | 96.41 | del(14q) | None |
| 5 | Yes | SMZL | 47 | 51.09 | No | V1-2*04 | 98.13 | del(14q) | KLF2, N0TCH2 |
| 6 | Yes | MZL H | 69 | 118.51 | No | V4-34*01/*02 | 94.14 | CK | TNFAIP3 |
| 7 | Yes | SMZL H | 57 | 45.9 | No | V5-51*01 | 96.63 | dup(3q) | None |
| 8 | Yes | LPL H | 150 | 35.94 | GK 1.0 | V4-34*01/*02 | 93.47 | CK | MYD88 |
| 9 | Yes | SLLU | 175 | 269 | ML 1.7 | V3-73*02 | 96.6 | t(2;7) | MYD88 |
| 10 | No | na | na | 171.86 | No | V3-66*01/*04 | 87.37 | None | None |
| 11 | No | na | na | 95.57 | No | V6-1*01 | 96.63 | +12 | None |
| 12 | No | na | na | 115.68 | No | V4-34*01/*02/*12 | 89.8 | +12 | None |
| 13 | No | na | na | 136.51 | No | V4-4*02 | 96.37 | None | CCND3 |
| 14 | No | na | na | 29.73 | GK 9.8 | V3-23*01/V3-23D*01 | 93.4 | +12 | MYD88 |
| 15 | No | na | na | 39.39 | No | V4-59*01 | 95.51 | i(17)(q10) | TP53, CCND3 |
| 16 | No | na | na | 53.85 | No | V3-66*02 | 100 | None | None |
| 17 | No | na | na | 126.78 | No | V4-59*01 | 97.54 | None | None |
| 18 | No | na | na | 39.66 | No | V3-7*02 | 96.88 | del(7q), +12 | TP53, CCND3 |
| 19 | No | na | na | 107.89 | GK 5.2 | V3-7*01 | 95.49 | None | MYD88 |
| 20 | No | na | na | 19.88 | MK 0.5 | V1-2*04 | 100 | None | None |
| 21 | No | na | na | 105 | No | V4-38-2*01 | 92.74 | None | None |
| 22 | No | na | na | 96.16 | No | V6-1*01(9 bp ins), V4-59*01 | 98.32, 91.93 | +3,+12, i(17)(q10) | None |
| 23 | No | na | na | 90.94 | No | V4-34*01/*02 | 95.92 | None | None |
| 24 | No | na | na | 88.41 | No | V4-34*01/*02 | 92.65 | None | None |
| 25 | No | na | na | 40.77 | No | V1-69*01/*11/*12/V1-69D*01 | 89.51 | None | None |
| 26 | No | na | na | 82 | ML trace | V4-34*01 | 100 | del(7q) | None |
| 27 | No | na | na | 149.13 | No | V4-30-2*01 | 91.7 | del(14q) | None |
| 28 | No | na | na | 75.43 | No | V3-9*01 | 93.06 | None | MAP2K1 |
| 29 | No | na | na | 160.72 | GK trace | V3-21*01/*02 | 94.76 | del(7q) | None |
| 30 | No | na | na | 68.34 | No | V1-3*01 | 93.85 | i(17)(q10) | None |
| 31 | No | na | na | 105.13 | No | V4-39*01 | 96.41 | None | None |
| 32 | No | na | na | 133.55 | No | V4-34*01 | 100 | del(7q) | None |
| 33 | No | na | na | 126.32 | MK trace | . | . | i(17)(q10) | None |
| 34 | No | na | na | 146.92 | No | V4-39*01 | 94.07 | +12 | None |
| 35 | No | na | na | 130.83 | No | V5-51*01 | 97.98 | None | None |
| 36 | No | na | na | 5192 | No | V3-23*01/V3-23D*01 | 96.18 | i(17)(q10) | None |
| 37 | No | na | na | 153.53 | GL trace | V1-69-2*01 | 96.63 | None | None |
CK, complex karyotype based on >3 G-banding aberrations; GL, G-lambda; H, histological diagnosis; MK, M-kappa; na, not applicable; SLLU, splenic B-cell lymphoma/leukemia unclassifiable.